Granted Patent B2

US 12,251,375 · App. 17/270,263 · Granted Mar 18, 2025

Inventors: Jong Seo Choi (Yongin-Si Gyeonggi-Do, KR); Min Soo Kim (Yongin-Si Gyeonggi-Do, KR); Shin Jung Park (Yongin-Si Gyeonggi-Do, KR); Jong Lae Lim (Yongin-Si Gyeonggi-Do, KR)

Assignee: CHONG KUN DANG PHARMACEUTICAL CORP.

A61K31/4439A61K9/16A61K9/1676A61K9/2095A61K9/2893A61K9/5026A61K9/5047A61K9/5073

Abstract

Claims (17)

1. A tablet comprising:

esomeprazole or a pharmaceutically acceptable salt thereof in the form of a pellet; and

sodium bicarbonate;

wherein:

the amount of esomeprazole or the pharmaceutically acceptable salt thereof is 20 mg to 40 mg as esomeprazole;

the total amount of sodium bicarbonate in the tablet is 800 mg;

the pellet comprises a first quantity of sodium bicarbonate, which comprises up to 30% by weight of the total weight of the sodium bicarbonate in the tablet;

the tablet is prepared by mixing the pellet with a second quantity of sodium bicarbonate or a granule comprising the second quantity of sodium bicarbonate, wherein the second quantity of sodium bicarbonate comprises 70% by weight or more of the total weight of the sodium bicarbonate in the tablet;

when the tablet is dissolved in a solution, the second quantity of sodium bicarbonate is first dissolved, and then the esomeprazole, or the pharmaceutically acceptable salt thereof is dissolved;

the tablet dissolves immediately in gastric juice;

when the tablet is singly administered orally to a subject, the pH in the stomach of the subject increases within 45 minutes; and when the tablet is dissolved in a solution at pH 1.2 by a flow through cell dissolution test method, the ratio of the time for the solution to reach a pH of 6.5 with respect to the time to reach the highest concentration of the esomeprazole or the pharmaceutically acceptable salt thereof is less than 1, and the time to reach the highest concentration of the esomeprazole or the pharmaceutically acceptable salt thereof is within 20 minutes.

2. The tablet according to claim 1 , characterized in that the pellet comprising the esomeprazole or the pharmaceutically acceptable salt thereof is coated with a coating agent, and does not comprise sodium bicarbonate.

3. The tablet according to claim 2 , characterized in that the coating agent is selected from the group consisting of polyvinyl alcohol, povidone, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinyl acetate, ethyl cellulose, and dimethylaminoethyl methacrylate⋅methyl methacrylate copolymer, or a combination thereof.

4. The tablet according to claim 1 , characterized in that the time to reach the highest concentration of the esomeprazole or the pharmaceutically acceptable salt thereof is between 5 minutes and 15 minutes.

5. The tablet according to claim 1 , characterized in that the esomeprazole or the pharmaceutically acceptable salt thereof is esomeprazole.

6. The tablet according to claim 1 , characterized in that the esomeprazole or the pharmaceutically acceptable salt thereof is esomeprazole magnesium salt.

7. The tablet according to claim 1 , characterized in that the esomeprazole or the pharmaceutically acceptable salt thereof is esomeprazole magnesium trihydrate.

Assignments (1)

Priority Claims (1)

Continuity (1)

References Cited (136)